1204 related articles for article (PubMed ID: 33861303)
1. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Herishanu Y; Avivi I; Aharon A; Shefer G; Levi S; Bronstein Y; Morales M; Ziv T; Shorer Arbel Y; Scarfò L; Joffe E; Perry C; Ghia P
Blood; 2021 Jun; 137(23):3165-3173. PubMed ID: 33861303
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
[TBL] [Abstract][Full Text] [Related]
4. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
[TBL] [Abstract][Full Text] [Related]
5. Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
Fiorcari S; Atene CG; Maffei R; Mesini N; Debbia G; Colasante C; Pozzi S; Barbieri E; Maccaferri M; Leonardi G; Potenza L; Luppi M; Marasca R
Hematol Oncol; 2023 Feb; 41(1):120-127. PubMed ID: 36156278
[TBL] [Abstract][Full Text] [Related]
6. Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Bagacean C; Letestu R; Al-Nawakil C; Brichler S; Lévy V; Sritharan N; Delmer A; Dartigeas C; Leblond V; Roos-Weil D; Tomowiak C; Merabet F; Béné MC; Clavert A; Chaoui D; Genet P; Guieze R; Laribi K; Drénou B; Willems L; Puppinck C; Legendre H; Troussard X; Malartre S; Cymbalista F; Michallet AS
Blood Adv; 2022 Jan; 6(1):207-211. PubMed ID: 34844264
[TBL] [Abstract][Full Text] [Related]
7. Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.
Benjamini O; Gershon R; Bar-Haim E; Lustig Y; Cohen H; Doolman R; Kedmi M; Ribakovsky E; Kneller A; Hod T; Erez N; Levy I; Rahav G; Avigdor A
Eur J Haematol; 2023 Jan; 110(1):99-108. PubMed ID: 36208015
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Perry C; Luttwak E; Balaban R; Shefer G; Morales MM; Aharon A; Tabib Y; Cohen YC; Benyamini N; Beyar-Katz O; Neaman M; Vitkon R; Keren-Khadmy N; Levin M; Herishanu Y; Avivi I
Blood Adv; 2021 Aug; 5(16):3053-3061. PubMed ID: 34387648
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
Benjamini O; Rokach L; Itchaki G; Braester A; Shvidel L; Goldschmidt N; Shapira S; Dally N; Avigdor A; Rahav G; Lustig Y; Ben David SS; Fineman R; Paz A; Bairey O; Polliack A; Levy I; Tadmor T
Haematologica; 2022 Mar; 107(3):625-634. PubMed ID: 34320789
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
12. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
Molica S; Tam C; Polliack A
Hematol Oncol; 2022 Aug; 40(3):313-319. PubMed ID: 35304771
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
Diamantopoulos PT; Kontandreopoulou CN; Stafylidis C; Vlachopoulou D; Giannakopoulou N; Vardaka M; Mpouhla A; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ann Hematol; 2022 Dec; 101(12):2711-2717. PubMed ID: 36271935
[TBL] [Abstract][Full Text] [Related]
14. Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination.
Lee HK; Hoechstetter MA; Buchner M; Pham TT; Huh JW; Müller K; Zange S; von Buttlar H; Girl P; Wölfel R; Brandmeier L; Pfeuffer L; Furth PA; Wendtner CM; Hennighausen L
Blood Adv; 2023 May; 7(10):2214-2227. PubMed ID: 36630562
[TBL] [Abstract][Full Text] [Related]
15. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
[TBL] [Abstract][Full Text] [Related]
16. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
[TBL] [Abstract][Full Text] [Related]
17. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
18. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study.
Diamantopoulos PT; Stafylidis C; Vlachopoulou D; Kontandreopoulou CN; Giannakopoulou N; Vardaka M; Mpouhla A; Mastrogianni E; Variami E; Galanopoulos A; Pappa V; Psichogiou M; Hatzakis A; Viniou NA
Ther Adv Hematol; 2022; 13():20406207221090150. PubMed ID: 35646300
[TBL] [Abstract][Full Text] [Related]
20. Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM; Koff JL; Blum KA; Ayers AA; O'Leary CB; Churnetski MC; Sulaiman S; Kives M; Sheng P; Davis CW; Nooka AK; Antia R; Dhodapkar MV; Suthar MS; Cohen JB; Ahmed R
J Clin Oncol; 2022 Sep; 40(26):3020-3031. PubMed ID: 35436146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
